^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    PGR positive

    i
    Other names: PGR, Progesterone receptor, Nuclear receptor subfamily 3 group C member 3, NR3C3
    Entrez ID:
    5241
    Related biomarkers:
    Expression
    Mutation
    Others
    9d
    PANSY: Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer (clinicaltrials.gov)
    P3, N=1560, Active, not recruiting, Fudan University | Recruiting --> Active, not recruiting | Trial completion date: Jul 2024 --> Jul 2027 | Trial primary completion date: Jul 2021 --> Jul 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    Herceptin (trastuzumab) • carboplatin • paclitaxel • docetaxel • Perjeta (pertuzumab) • cyclophosphamide • epirubicin
    14d
    Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer (clinicaltrials.gov)
    P1, N=44, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Nov 2025 --> Nov 2026
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    HER-2 negative • PGR positive
    |
    carboplatin • veliparib (ABT-888)
    14d
    HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer (clinicaltrials.gov)
    P1, N=54, Active, not recruiting, Abramson Cancer Center at Penn Medicine | Trial completion date: Aug 2025 --> Dec 2025
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    PGR positive
    |
    Lynparza (olaparib) • Ibrance (palbociclib) • fulvestrant
    25d
    Curcumin in Reducing Joint Pain in Breast Cancer Survivors With Aromatase Inhibitor-Induced Joint Disease (clinicaltrials.gov)
    P=N/A, N=42, Active, not recruiting, City of Hope Medical Center | Trial completion date: Oct 2025 --> Sep 2026 | Trial primary completion date: Oct 2025 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • PGR positive
    25d
    Encapsulated papillary carcinoma with invasion in the breast: A case report with imaging findings. (PubMed, Radiol Case Rep)
    Postoperative recovery was uneventful, and she remained recurrence-free on tamoxifen therapy for 2 years. This case highlights key imaging features suggestive of invasion in EPC, which may facilitate preoperative assessment and management.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    tamoxifen
    1m
    A Study of Flibanserin in Breast Cancer Survivors on Tamoxifen or Aromatase Inhibitors (clinicaltrials.gov)
    P2, N=43, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Oct 2025 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    PGR (Progesterone receptor)
    |
    PGR positive
    |
    tamoxifen
    1m
    Advanced dual primary male breast cancer and lung cancer: A case report and literature review. (PubMed, Oncol Lett)
    Treatment consisted of neoadjuvant chemotherapy (epirubicin + carboplatin + trastuzumab + pertuzumab), a modified radical mastectomy with latissimus dorsi flap reconstruction and a thoracoscopic lung wedge resection. The therapeutic approach resulted in partial remission of the breast cancer prior to surgery and a stable disease status in the lung, with no recurrence at the 1-year follow-up. This case underscores the importance of comprehensive, integrative strategies and long-term follow-up for managing rare, complex cancer cases.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • PGR positive • EGFR positive
    |
    Herceptin (trastuzumab) • carboplatin • Perjeta (pertuzumab) • epirubicin
    1m
    Exploratory Clinical Study of Camrelizumab Combined with Pirfenidone and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer (ChiCTR2500109774)
    P2, N=12, Not yet recruiting, Harbin medical university cancer hospital; Harbin medical university cancer hospital
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • ER negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    AiRuiKa (camrelizumab) • Halaven (eribulin mesylate)
    1m
    A single-center, randomized, non-comparative, phase II clinical trial of low-dose neratinib maleate combined with trastuzumab biosimilar and albumin paclitaxel neoadjuvant in the treatment of HER-2-positive/HR-positive early or locally advanced breast cancer (ChiCTR2500108275)
    P=N/A, N=80, Not yet recruiting, West China Hospital of Sichuan University; West China Hospital of Sichuan University
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • ER positive • HER-2 amplification • HER-2 expression • PGR positive • HER-2 amplification + HR-positive
    |
    carboplatin • docetaxel • Nerlynx (neratinib) • Perjeta (pertuzumab) • albumin-bound paclitaxel
    1m
    A Phase II Clinical Trial of artificial intelligence-assisted one-stop radiotherapy for breast cancer after total mastectomy (ChiCTR2500107813)
    P2, N=325, Not yet recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
    New P2 trial
    |
    PGR (Progesterone receptor)
    |
    HER-2 positive • PGR positive
    1m
    CLEE011X2107: Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer (clinicaltrials.gov)
    P1/2, N=255, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Dec 2025 --> Feb 2027 | Trial primary completion date: Dec 2025 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • PGR positive
    |
    Piqray (alpelisib) • Kisqali (ribociclib) • letrozole
    1m
    NORDIS: Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma (clinicaltrials.gov)
    P=N/A, N=50, Recruiting, Stanford University | Trial completion date: Sep 2025 --> Dec 2025 | Trial primary completion date: Sep 2025 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • ER positive • PGR positive